CGT Catapult has enabled significant growth in the UK advanced therapies sector since its founding in 2012. It provides expertise and infrastructure that have contributed to over £5.5 billion received by ATMP companies in the UK since inception. The number of active clinical trials has more than doubled since its launch. CGT Catapult’s facilities support process development through to commercial-scale manufacturing for cell and gene therapy developers.
INmune Bio Inc.: Partnership to scale up commercial-ready manufacturing for CORDStrom™ cell therapy targeting RDEB.Quell Therapeutics: Manufacturing partnership for engineered Treg cell therapies targeting neuroinflammatory/autoimmune conditions.Securecell AG/DataHow AG/ChemoMetec/HORIBA UK Ltd.: Consortium project on bioprocess automation/digitalization for AAV gene therapy manufacturing.FourPlus/Holosphere/Innovate UK collaboration on VR training platforms for CGT professionals.
Beyond the preview
Go deeper on Cell and Gene Therapy Catapult.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
Trial phase
Status
Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
Partners
Deal terms
Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
Funding rounds
Investors
Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
Peer companies
Targets
Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
Platforms
Patents
Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
Company news
Sources
Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cell and Gene Therapy Catapult.